First-in-human study of MW151, a novel drug targeting neuroinflammation

Project: Research project

Project Details

Description

A critical mechanism driving the pathological progression of neurodegenerative disease is dysregulated inflammation in the brain. Neuroinflammatory repair processes are fundamental to CNS homeostasis. However, inflammation that is inefficient, excessive, or prolonged can result in tissue damage. Dysregulated neuroinflammation responses such as proinflammatory cytokine overproduction from abnormally activated glia are seen early in progressive neurodegenerative disorders such as Alzheimer’s disease (AD) and related dementias, and are a key contributor to synaptic dysfunction, neurodegeneration and cognitive decline.
StatusFinished
Effective start/end date9/30/185/31/21

Funding

  • ImmunoChem Therapeutics, LLC (SP0047505, 10/31/18 // 4R44AG060846-02 REVISED)
  • National Institute on Aging (SP0047505, 10/31/18 // 4R44AG060846-02 REVISED)

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.